PE20090904A1 - ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b - Google Patents
ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2bInfo
- Publication number
- PE20090904A1 PE20090904A1 PE2008001198A PE2008001198A PE20090904A1 PE 20090904 A1 PE20090904 A1 PE 20090904A1 PE 2008001198 A PE2008001198 A PE 2008001198A PE 2008001198 A PE2008001198 A PE 2008001198A PE 20090904 A1 PE20090904 A1 PE 20090904A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- amino
- hydroxyetoxy
- dicarbonitrile
- oxazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Abstract
REFERIDA A UN DERIVADO DE ARILOXAZOL DE FORMULA (I), DONDE A ES O O S; R1 ES H O ALQUILO C1-C4; R2 ES H O ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON OH, ALCOXI C1-C4 O F; R3 ES H, HALOGENO O ALQUILO C1-C4; R4 Y R5 SON H O ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON OH, ALCOXI C1-C4, AMINO, ENTRE OTROS; R6 ES ARILO C6-C10 O HETEROARILO DE 5 A 10 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON HALOGENO, CIANO, NITRO, ENTRE OTROS; R7 ES H, F, ALQUILO C1-C4, TRIFLUOROMETILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-AMINO-6-({[2-(3-CLORO-4-FLUOROFENIL)-1,3-OXAZOL-4-IL]METIL}SULFANIL)-4-[4-(2-HIDROXIETOXI)FENIL]PIRIDIN-3,5-DICARBONITRILO, 2-AMINO-6-({[2-(3,4-DIFLUOROFENIL)-1,3-OXAZOL-4-IL]METIL}SULFANIL)-4-[4-(2-HIDROXIETOXI)FENIL]PIRIDIN-3,5-DICARBONITRILO, 2-AMINO-6-({[2-(4-FLUORO-3-METILFENIL)-1,3-OXAZOL-4-IL]METIL}SULFANIL)-4-[4-(2-HIDROXIETOXI)FENIL]PIRIDIN-3,5-DICARBONITRILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, UROGENITALES, INFLAMATORIAS, ENTRE OTRAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007035367A DE102007035367A1 (de) | 2007-07-27 | 2007-07-27 | Substituierte Aryloxazole und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090904A1 true PE20090904A1 (es) | 2009-08-08 |
Family
ID=39855432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001198A PE20090904A1 (es) | 2007-07-27 | 2008-07-16 | ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b |
Country Status (15)
Country | Link |
---|---|
US (2) | US8440700B2 (es) |
EP (1) | EP2185550B1 (es) |
JP (1) | JP5307136B2 (es) |
KR (1) | KR20100039358A (es) |
CN (1) | CN101939317A (es) |
AR (1) | AR067646A1 (es) |
AT (1) | ATE531712T1 (es) |
CA (1) | CA2694270A1 (es) |
CL (1) | CL2008002076A1 (es) |
DE (1) | DE102007035367A1 (es) |
ES (1) | ES2375506T3 (es) |
PE (1) | PE20090904A1 (es) |
TW (1) | TW200922575A (es) |
UY (1) | UY31228A1 (es) |
WO (1) | WO2009015776A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102008013587A1 (de) * | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
EP2297104B1 (de) | 2008-05-29 | 2013-08-07 | Bayer Intellectual Property GmbH | 2-alkoxy-substituierte dicyanopyridine und ihre verwendung |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102008062566A1 (de) * | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
US9751847B2 (en) * | 2010-10-14 | 2017-09-05 | University Of Utah Research Foundation | Methods and compositions related to neuroactive thiazoline compounds |
CN103570705B (zh) * | 2012-07-18 | 2017-01-25 | 中国医学科学院医药生物技术研究所 | 取代的n‑((1',3'‑杂唑‑4'‑基)‑甲基)‑4‑苯甲酰基六氢吡啶类化合物及其用途 |
WO2017137528A1 (en) | 2016-02-12 | 2017-08-17 | Charité - Universitätsmedizin Berlin | Adenosine a1 receptor agonist for use in treatment of status epilepticus |
WO2018153900A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern |
WO2018153895A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten |
WO2018153897A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern |
WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
WO2018153898A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
WO2023158725A1 (en) * | 2022-02-17 | 2023-08-24 | Lucy Therapeutics, Inc. | Adenosine ligands for the treatment of neurological disorders |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4052510A (en) | 1974-12-18 | 1977-10-04 | Sandoz, Inc. | 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity |
TW299333B (es) | 1992-12-29 | 1997-03-01 | Takeda Pharm Industry Co Ltd | |
ATE182332T1 (de) | 1994-06-16 | 1999-08-15 | Pfizer | Pyrazolo und pyrrolopyridine |
DE4430638A1 (de) | 1994-08-29 | 1996-03-07 | Bayer Ag | Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel |
JPH09132529A (ja) | 1995-11-09 | 1997-05-20 | Ono Pharmaceut Co Ltd | 一酸化窒素合成酵素阻害剤 |
KR19990077319A (ko) | 1996-01-17 | 1999-10-25 | 한센 핀 베네드, 안네 제헤르 | 축합된 1,2,4-티아디아진 및 축합된 1,4-티아진 유도체, 그것의제조방법 및 사용 |
AU709190B2 (en) | 1996-01-29 | 1999-08-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
JPH10324687A (ja) | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | ピロール化合物、製法および農園芸用殺菌剤 |
WO1998054139A1 (de) | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Verfahren zur herstellung substituierter thiopyridine |
WO1999003861A1 (en) | 1997-07-16 | 1999-01-28 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19947154A1 (de) | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
CZ20023199A3 (cs) | 2000-02-25 | 2003-05-14 | F. Hoffmann-La Roche Ag | Modulátory receptoru adenosinu |
CA2415899A1 (en) | 2000-07-18 | 2003-01-13 | Chikashi Saitoh | Medicine comprising dicyanopyridine derivative |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
EP1341772A2 (en) | 2000-12-11 | 2003-09-10 | E. I. du Pont de Nemours and Company | Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests |
ATE318812T1 (de) | 2000-12-21 | 2006-03-15 | Bristol Myers Squibb Co | Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie |
DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10134481A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10238113A1 (de) | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
JP2003183254A (ja) | 2001-12-20 | 2003-07-03 | Yamanouchi Pharmaceut Co Ltd | 2−アシルアミノ−3,5−ジシアノピリジン誘導体又はその塩 |
US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
EP1388342A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
MXPA05001688A (es) | 2002-08-12 | 2005-04-19 | Sugen Inc | 3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos. |
CA2508780A1 (en) | 2002-12-12 | 2004-07-01 | Pharmacia Corporation | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
JP4722851B2 (ja) | 2003-09-23 | 2011-07-13 | メルク・シャープ・エンド・ドーム・コーポレイション | キノリンカリウムチャネル阻害剤 |
US7338951B2 (en) | 2003-11-10 | 2008-03-04 | Synta Pharmaceuticals Corp. | Pyridine compounds |
US20050182105A1 (en) | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
MXPA06015002A (es) | 2004-06-25 | 2007-02-08 | Taisho Pharma Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con tetrahidropiridina como antagonistas de crf. |
DE102004032651A1 (de) | 2004-07-06 | 2006-02-16 | Bayer Healthcare Ag | Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen |
DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
AU2005286653A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-CoA-desaturase |
CA2602514A1 (en) | 2005-03-24 | 2006-09-28 | Bayer Healthcare Ag | Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage |
US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
JP5201817B2 (ja) * | 2005-10-28 | 2013-06-05 | 大塚製薬株式会社 | 医薬組成物 |
WO2007073855A1 (en) | 2005-12-23 | 2007-07-05 | Bayer Healthcare Ag | Use of adenosine a1 receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases |
DE102006009813A1 (de) | 2006-03-01 | 2007-09-06 | Bayer Healthcare Ag | Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel |
JP2009535307A (ja) | 2006-04-28 | 2009-10-01 | アベキサ・リミテッド | インテグラーゼ阻害剤3 |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
EP2297104B1 (de) | 2008-05-29 | 2013-08-07 | Bayer Intellectual Property GmbH | 2-alkoxy-substituierte dicyanopyridine und ihre verwendung |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
-
2007
- 2007-07-27 DE DE102007035367A patent/DE102007035367A1/de not_active Withdrawn
-
2008
- 2008-07-15 CL CL2008002076A patent/CL2008002076A1/es unknown
- 2008-07-16 PE PE2008001198A patent/PE20090904A1/es not_active Application Discontinuation
- 2008-07-16 UY UY31228A patent/UY31228A1/es not_active Application Discontinuation
- 2008-07-17 US US12/671,019 patent/US8440700B2/en not_active Expired - Fee Related
- 2008-07-17 KR KR1020107001748A patent/KR20100039358A/ko not_active Application Discontinuation
- 2008-07-17 CN CN2008801002064A patent/CN101939317A/zh active Pending
- 2008-07-17 JP JP2010518527A patent/JP5307136B2/ja not_active Expired - Fee Related
- 2008-07-17 CA CA2694270A patent/CA2694270A1/en not_active Abandoned
- 2008-07-17 AT AT08774012T patent/ATE531712T1/de active
- 2008-07-17 EP EP08774012A patent/EP2185550B1/de not_active Not-in-force
- 2008-07-17 WO PCT/EP2008/005833 patent/WO2009015776A1/de active Application Filing
- 2008-07-17 ES ES08774012T patent/ES2375506T3/es active Active
- 2008-07-22 AR ARP080103173A patent/AR067646A1/es unknown
- 2008-07-25 TW TW097128216A patent/TW200922575A/zh unknown
-
2013
- 2013-05-14 US US13/893,344 patent/US9095582B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20110130377A1 (en) | 2011-06-02 |
AR067646A1 (es) | 2009-10-21 |
US20140162981A1 (en) | 2014-06-12 |
CL2008002076A1 (es) | 2009-01-30 |
DE102007035367A1 (de) | 2009-01-29 |
EP2185550B1 (de) | 2011-11-02 |
CN101939317A (zh) | 2011-01-05 |
CA2694270A1 (en) | 2009-02-05 |
KR20100039358A (ko) | 2010-04-15 |
JP5307136B2 (ja) | 2013-10-02 |
US9095582B2 (en) | 2015-08-04 |
UY31228A1 (es) | 2009-03-02 |
JP2010534693A (ja) | 2010-11-11 |
TW200922575A (en) | 2009-06-01 |
ATE531712T1 (de) | 2011-11-15 |
EP2185550A1 (de) | 2010-05-19 |
ES2375506T3 (es) | 2012-03-01 |
WO2009015776A1 (de) | 2009-02-05 |
US8440700B2 (en) | 2013-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090904A1 (es) | ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b | |
PE20120058A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
PE20091818A1 (es) | DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
PE20070004A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
PE20080925A1 (es) | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA) | |
AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
PE20100737A1 (es) | Nuevos compuestos | |
PE20110991A1 (es) | Compuestos de fenil-piridazinona-pirazol-fenilo como inhibidores de pde | |
UY30323A1 (es) | Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas | |
PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
UY32147A (es) | Derivados de indol y de indolina y métodos para usarlos | |
PA8632701A1 (es) | Compuestos terapeuticos | |
PE20120002A1 (es) | Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2 | |
PE20070172A1 (es) | DERIVADOS BICICLICOS COMO INHIBIDORES DE p38 | |
PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
RS51137B (sr) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
PE20141308A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
ATE442356T1 (de) | 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung | |
PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
PE20080948A1 (es) | Derivados de imidazol como moduladores de la senda de hedgehog | |
PE20081393A1 (es) | Derivados de quinolina como inhibidores de csf-1r |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |